Dr Bishal Gyawali

Bishal Gyawali, MD, PhD, FASCO is a medical oncologist and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. He did his cancer policy fellowship at Harvard Medical School. His clinical expertise is across multiple adult solid tumors, with special focus on GI and GU malignancies. He is in the editorial and advisory board for multiple medicine and oncology journals and has authored or co-authored more than 200 peer-reviewed articles in high-impact journals. Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term “cancer groundshot” and chaired a session on the same at ASCO 2022. His interviews and studies have been reported in several influential media such as CNN, NPR, Washington Post, STAT News etc. He is a member of the ESMO-Magnitude of Clinical Benefit Scale and ESMO Public Policy committees. He was a member of ASCO-Health Equity and Outcomes Committee 2021-2024, and is now a member of ASCO International Affairs Committee 2024-2027. He is a graduate of ASCO Leadership Development Program, Class of 2023-2024. In 2023, he co-founded Common Sense Oncology, a growing movement of oncology physicians, patients, advocates, researchers, and stakeholders dedicated to working together to ensure that cancer treatments improve outcomes that matter to patients, and access to such treatments are equitable globally.